THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ JANUARY/FEBRUARY 2010
VOLUME 3, NUMBER 1
FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS
REGULATORY
Orphan Drug Pricing and Payer Management in the United States: Are We Approaching the Tipping Point? Rebecca Hyde; Diana Dobrovolny
Stakeholder Perspective by Kavita V. Nair, PhD BUSINESS
™
Physicians’ Perceptions of Reimbursement as a Barrier to Comprehensive Diabetes Care Alyssa Pozniak, PhD; Lois Olinger, MA; Victoria Shier, MA
Stakeholder Perspective by Gary M. Owens, MD CLINICAL
Hypertension Management: An Update Quang Nguyen, DO; Joann Dominguez, MD; Loida Nguyen, PharmD; Nageshwara Gullapalli, MD
Stakeholder Perspective by Lekshmi Dharmarajan, MD, FACP, FACC DEPARTMENTS ◆ Generic Drug Trends
Competition from Biosimilars an Incentive for Innovation ◆ Industry Trends
Emerging Trends in Breast Cancer Management ◆ Drug Pipeline
Rheumatology Pipeline Boasts Innovation, ID Line Is Drying Up: ACR/IDSA 2009 Cardiology Pipeline Is Promising: AHA 2009
©2010 Engage Healthcare Communications, LLC www.AHDBonline.com